Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.
A series of recent studies has demonstrated that the molecules involved in regulation of neuronal plasticity are also involved in the mode of action of antidepressants and mood stabilizer drugs. Intracellular calcium signaling, energy metabolism, and neuronal plasticity can be influenced by inducing axonal remodeling and increasing levels of certain synaptic proteins. Because antipsychotic drugs are used as mood stabilizers our studies focused on a newly-marketed antipsychotic drug, paliperidone. We determined changes in rat synaptoneurosomal proteins after chronic treatment with paliperidone, lithium salt, or valproic acid in order to find similarities or differences between the mode of action of paliperidone and these two classical mood stabilizers. We determined differential protein expression profiles in prefrontal cortex (PFC) of male Sprague-Dawley rats (n = 4/group). Synaptoneurosomal-enriched preparations were obtained from PFC after chronic treatment with these three drugs. Proteins were separated by 2D-DIGE and identified by nano-LC-MS/MS. We observed similar protein expression profiles at the synaptoneurosomal level, suggesting that the mode of action for paliperidone is similar to that of lithium and valproic acid. However, the expression profile for paliperidone was more similar to that of lithium. Pathways affected in common by these two drugs included oxidative phosphorylation, electron transport, carbohydrate metabolism, and post-synaptic cytokinesis implicating the effects of these drugs in signaling pathways, energy metabolism, and synaptic plasticity.
Corena-McLeod
Maria del Pilar
Mdel P
Neuropsychopharmacology Laboratory, Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. corena.maria@mayo.edu
Oliveros
Alfredo
A
Charlesworth
Cristine
C
Madden
Benjamin
B
Liang
Yian Qi
YQ
Boules
Mona
M
Shaw
Amanda
A
Williams
Katrina
K
Richelson
Elliott
E
D000818:Animals; D018692:Antimanic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology; D004334:Drug Administration Schedule; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D007555:Isoxazoles / Q000008:administration & dosage / Q000494:pharmacology*; D018020:Lithium Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009419:Nerve Tissue Proteins / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects; D000068882:Paliperidone Palmitate; D017397:Prefrontal Cortex / Q000187:drug effects*; D020543:Proteome / Q000187:drug effects; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013574:Synaptosomes / Q000187:drug effects; D014635:Valproic Acid / Q000008:administration & dosage / Q000494:pharmacology*
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D007555:Isoxazoles; D018020:Lithium Compounds; D009419:Nerve Tissue Proteins; D020543:Proteome; D011743:Pyrimidines; D014635:Valproic Acid; D000068882:Paliperidone Palmitate